Bibliography
Introduction
Listed below are some of the recent publications from the Hepatic, Pancreatic and Bilary Disease Unit, which is part of the University Hospitals of Leicester.
Bibliography
1: Cai H, Raynaud D, Steward WP, Gescher AJ. A simple HPLC method for the determination of apigenin in mouse tissues. Biomed Chromatogr. 2006 Feb 28
2: Sale S, Tunstall RG, Ruparelia KC, Butler PC, Potter GA, Steward WP, Gescher AJ. Effects of the potential chemopreventive agent DMU-135 on adenoma development in the Apc(Min+) mouse. Invest New Drugs. 2006 Feb 24
3: Tunstall RG, Sharma RA, Perkins S, Sale S, Singh R, Farmer PB, Steward WP, Gescher AJ. Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trials. Eur J Cancer. 2006 Feb;42(3):415-21.
4: D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol. 2005 Nov;6(11):899-904.
5: Almeida GM, Duarte TL, Steward WP, Jones GD. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst). 2006 Feb 3;5(2):219-25.
6: Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Cancer Chemother Pharmacol. 2005 Sep 20:1-11
7: Cai H, Al-Fayez M, Tunstall RG, Platton S, Greaves P, Steward WP, Gescher AJ. The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice. Mol Cancer Ther. 2005 Sep;4(9):1287-92.
8: Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 2005 Oct;41(15):2213-36
9: Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy.
Pancreatology. 2005;5(6):514-29
10: Cooke D, Steward WP, Gescher AJ, Marczylo T. Anthocyans from fruits and vegetables--does bright colour signal cancer chemopreventive activity? Eur J Cancer. 2005 Sep;41(13):1931-40.
11: Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005 Sep;41(13):1955-68.
12: Gescher A, Steward WP. Cancer chemoprevention--an update on a (still) novel and exciting field of oncology. Eur J Cancer. 2005 Sep;41(13):1831-2. No abstract available.
13: Verschoyle RD, Greaves P, Cai H, Borkhardt A, Broggini M, D'Incalci M, Riccio E, Doppalapudi R, Kapetanovic IM, Steward WP, Gescher AJ. Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemother Pharmacol. 2006 Jan;57(1):1-6
14: O'Byrne KJ, Steward WP. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. Expert Opin Emerg Drugs. 2001 Apr;6(1):155-74.
15: Sherwood BT, Jones GD, Mellon JK, Kockelbergh RC, Steward WP, Symonds RP. Concomitant chemoradiotherapy for muscle-invasive bladder cancer: the way
forward for bladder preservation? Clin Oncol (R Coll Radiol). 2005 May;17(3):160-6.
16: Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol. 2005 Jun 20;23(18):4162-71.
17: Garcea G, Lloyd T, Steward WP, Dennison AR, Berry DP. Differences in attitudes between patients with primary colorectal cancer and patients with secondary colorectal cancer: is it reflected in their willingness to participate in drug trials?
Eur J Cancer Care (Engl). 2005 May;14(2):166-70.
18: Cai H, Steward WP, Gescher AJ. Determination of the putative cancer chemopreventive flavone tricin in plasma and tissues of mice by HPLC with UV--visible detection. Biomed Chromatogr. 2005 Sep;19(7):518-22.
19: Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marme D. Soluble markers for the assessment of biological activity with PTK787/ZK 222584(PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol. 2005 Apr;16(4):558-65
20: Ahmed SI, Thomas AL, Steward WP. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother. 2004 Nov;16 Suppl 4:59-63. Review.
21: Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its
synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon
cancer cells. Int J Cancer. 2005 Jun 10;115(2):194-201.
22: Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5.
23: Manson MM, Farmer PB, Gescher A, Steward WP. Innovative agents in cancer prevention. Recent Results Cancer Res. 2005;166:257-75. Review.
24: Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TR, Gescher AJ. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis:
targets for chemopreventive strategies. Eur J Cancer. 2005 Jan;41(1):61-70. Review.
25: Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004 Oct 15;10(20):6847-54.
26: Morgan B, Horsfield MA, Steward WP. The role of imaging in the clinical development of antiangiogenic agents. Hematol Oncol Clin North Am. 2004 Oct;18(5):1183-206, x. Review.
27: Cai H, Hudson EA, Mann P, Verschoyle RD, Greaves P, Manson MM, Steward WP, Gescher AJ. Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells in vitro and in nude
mice in vivo. Br J Cancer. 2004 Oct 4;91(7):1364-71.
28: Donald S, Verschoyle RD, Greaves P, Colombo T, Zucchetti M, Falcioni C, Zaffaroni M, D'Incalci M, Manson MM, Jimeno J, Steward WP, Gescher AJ.
Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer. 2004 Oct 10;111(6):961-7.
29: Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, Steward WP, Williams ML. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice.
Clin Cancer Res. 2004 Aug 1;10(15):5233-41.
30: Garcea G, Lloyd TD, Gescher A, Dennison AR, Steward WP, Berry DP. Angiogenesis of gastrointestinal tumours and their metastases--a target for
intervention? Eur J Cancer. 2004 Jun;40(9):1302-13. Review.
31: Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos. 2004 Jun;32(6):632-8.
32: Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004 Mar 8;90(5):1011-5.
33: Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP, Gescher AJ. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer. 2004 Feb 9;90(3):736-44.
34: Moneef MA, Sherwood BT, Bowman KJ, Kockelbergh RC, Symonds RP, Steward WP, Mellon JK, Jones GD. Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Br J Cancer. 2003 Dec 15;89(12):2271-6.
35: Ratan HL, Gescher A, Steward WP, Mellon JK. ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int. 2003 Dec;92(9):890-5. Review. No abstract available.
36: Cai H, Verschoyle RD, Steward WP, Gescher AJ. Determination of the flavone tricin in human plasma by high-performance liquid chromatography. Biomed Chromatogr. 2003 Oct;17(7):435-9.
37: Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):953-7.
38: Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A,
Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003 Nov 1;21(21):3955-64
39: Garcea G, Dennison AR, Steward WP, Berry DP. Chemoprevention of gastrointestinal malignancies. ANZ J Surg. 2003 Sep;73(9):680-6. Review.
40: Sharma RA, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer
Oncol Rep. 2003 Sep-Oct;10(5):1625-31
41: Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F, Evans
TR. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer. 2003 Jul 21;89(2):252-7.
42: Smith LK, Botha JL, Benghiat A, Steward WP. Latest trends in cancer incidence among UK South Asians in Leicester. Br J Cancer. 2003 Jul 7;89(1):70-3.
43: Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol. 2003 Jun;30(3 Suppl 6):32-8
44: Colquhoun AJ, Jones GD, Moneef MA, Bowman KJ, Kockelbergh RC, Symonds RP, Steward WP, Mellon JK. Improving and predicting radiosensitivity in muscle invasive bladder cancer. J Urol. 2003 Jun;169(6):1983-92. Review.
45: Garcea G, Sharma RA, Dennison A, Steward WP, Gescher A, Berry DP. Molecular biomarkers of colorectal carcinogenesis and their role in
surveillance and early intervention. Eur J Cancer. 2003 May;39(8):1041-52. Review.
46: Anderton MJ, Jukes R, Lamb JH, Manson MM, Gescher A, Steward WP, Williams ML. Liquid chromatographic assay for the simultaneous determination of
indole-3-carbinol and its acid condensation products in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Apr 25;787(2):281-91.
47: Gescher AJ, Sharma RA, Steward WP. Cancer prevention and delay are as important as cure. Lancet Oncol. 2003 Feb;4(2):72-3. No abstract available.
48: Ratan HL, Steward WP, Gescher AJ, Mellon JK. Resveratrol--a prostate cancer chemopreventive agent? Urol Oncol. 2002 Nov-Dec;7(6):223-7
49: Thomas AL, Steward WP. Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. Expert Rev Anticancer Ther. 2001 Aug;1(2):258-68.
50: O'Byrne KJ, Thomas AL, Sharma RA, DeCatris M, Shields F, Beare S, Steward WP. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in
metastatic breast cancer. Br J Cancer. 2002 Jul 1;87(1):15-20.
51: Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40.
52: Gescher AJ, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol. 2001 Jun;2(6):371-9.
53: Sharma RA, Harris AL, Dalgleish AG, Steward WP, O'Byrne KJ. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol. 2001 Dec;2(12):726-32
54: Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):105-11.
55: Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic
biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1295-9.
56: Sharma RA, Symonds RP, O'Byrne KJ, Cheater F, Abrams KR, Steward WP. Involving patients in treatment decisions: can we learn from clinical trials?
Clin Oncol (R Coll Radiol). 2001;13(5):328-32.
57: Thomas AL, O'Byrne K, Furber L, Jeffery K, Steward WP. A phase II study of caelyx, liposomal doxorubicin: lack of activity in patients
with advanced gastric cancer. Cancer Chemother Pharmacol. 2001 Oct;48(4):266-8.
58: Sharma RA, Eatock MM, Twelves CJ, Brown G, McLelland HR, Clayton KT, O'Byrne KJ, Moyses C, Carmichael J, Steward WP. Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemother Pharmacol. 2001 Sep;48(3):197-201.
59: Sharma RA, Gescher A, Plastaras JP, Leuratti C, Singh R, Gallacher-Horley B, Offord E, Marnett LJ, Steward WP, Plummer SM. Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts ofdeoxyguanosine in human colon cells. Carcinogenesis. 2001 Sep;22(9):1557-60.
60: Sharma RA, Gescher AJ, O'Byrne KJ, Steward WP. Familiar drugs may prevent cancer. Postgrad Med J. 2001 Aug;77(910):492-7. Review.
61: Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL,
Verweij J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res. 2001 Jul;7(7):1912-22.
62: Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001 Jul;7(7):1894-900.
63: Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP, Gescher A. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res. 2001 May;7(5):1452-8.
64: Sharma RA, Steward WP, West KP, Hemingway D. Toxic megacolon: remember cytomegalovirus. Hosp Med. 2001 Mar;62(3):178-9. No abstract available.
65: O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy. 2001;47 Suppl 2:78-108.
66: Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A. Characterization of metabolites of the chemopreventive agent curcumin in humanand rat hepatocytes and in the rat in vivo, and evaluation of their ability toinhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001 Feb 1;61(3):1058-64.
67: Sharma RA, Manson MM, Gescher A, Steward WP. Colorectal cancer chemoprevention: biochemical targets and clinical developmentof promising agents.
Eur J Cancer. 2001 Jan;37(1):12-22.
68: Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 2000 Dec;36(18):2329-34.
69: Steward WP, Thomas AL. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs. 2000 Dec;9(12):2913-22.
70: Dobbs SP, Brown LJ, Ireland D, Abrams KR, Murray JC, Gatter K, Harris A, Steward WP, O'Byrne KJ. Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Ann Diagn Pathol. 2000 Oct;4(5):286-92.
71: Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer. 2000 Sep;29(3):169-77.
72: Cox G, Walker RA, Muller S, Abrams KR, Steward WP, O'Byrne KJ. Does immunointensity account for the differences in prognostic significance of
Bcl-2 expression in non-small cell lung cancer? Pathol Oncol Res. 2000;6(2):87-92.
73: Thomas AL, O'Byrne K, Steward WP. Chemotherapy for upper gastrointestinal tumours. Postgrad Med J. 2000 Jun;76(896):321-7. Review.
74: O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000 Apr;82(8):1427-32.
75: O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis
and the progression of malignant disease. Eur J Cancer. 2000 Jan;36(2):151-69.
76: Cox G, Jones JL, Walker RA, Steward WP, O'Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer. 2000 Feb;27(2):81-100. Review.
77: Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. J Clin Oncol. 1999 Oct;17(10):3260-9.
78: Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H.
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
Br J Cancer. 1999 May;80(3-4):396-402.
79: Steward WP. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol. 1999;43 Suppl:S56-60. Review.
80: Cox G, Steward WP, O'Byrne KJ. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax. 1999 Feb;54(2):169-79.
81: O'Byrne KJ, Steward WP. The promise of improved drug delivery. Clin Sci (Lond). 1999 Feb;96(2):127-8.
82: Thomas A, Steward WP. Gemcitabine--a major advance? Ann Oncol. 1998 Dec;9(12):1265-7
83: O'Byrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas.Oncology. 1999;56(1):13-23..
84: Abratt RP, Sandler A, Crino L, Steward WP, Shepherd FA, Green MR, Nguyen B, Peters GJ. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol. 1998 Aug;25(4 Suppl 9):35-43.
85: Steward WP. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer. 1998;78 Suppl 3:15-9
86: O'Byrne K, Steward WP. The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. Crit Rev Oncol Hematol. 1998 Apr;27(3):221-7
87: Dunlop DJ, Eatock MM, Paul J, Anderson S, Reed NS, Soukop M, Lucie N, Fitzsimmons EJ, Tansey P, Steward WP. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol). 1998;10(2):107-14.
88: Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective
randomized study of 300 patients. J Clin Oncol. 1998 Feb;16(2):642-50.
89: Steward WP. Chemotherapy for metastatic soft tissue sarcomas. Cancer Treat Res. 1997;91:157-72.
90: Steward WP, Dunlop DJ, Dabouis G, Lacroix H, Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin Oncol. 1996 Oct;23(5 Suppl 10):43-7.
91: Alcorn MJ, Holyoake TL, Richmond L, Pearson C, Farrell E, Kyle B, Dunlop DJ, Fitzsimons E, Steward WP, Pragnell IB, Franklin IM. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol. 1996 Jun;14(6):1839-47.
92: Holyoake TL, Freshney MG, McNair L, Parker AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ, Pragnell IB. Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood. 1996 Jun 1;87(11):4589-95.
93: Beare S, Steward WP. Plasma free iron and chemotherapy toxicity. Lancet. 1996 Feb 10;347(8998):342-3
94: Steward WP, Dunlop DJ, Cameron C, Talbot DC, Kleisbauer JP, Thomas P, Guerin JC, Perol M, Sanson C, Dabouis G, et al. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study. Anticancer Drugs. 1995 Dec;6 Suppl 6:33-7.
95: Seymour AM, de Campos E, Thatcher N, De Greve J, Cunningham D, Howell A,
Tueni E, Bron DG, Steward WP, Berdel WE, et al. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Eur J Cancer. 1995 Dec;31A(13-14):2157-63.
96: Dancey J, Steward WP. The role of vindesine in oncology--recommendations after 10 years' experience. Anticancer Drugs. 1995 Oct;6(5):625-36. Review.
97: Hatton MQ, Cassidy J, Bicknell S, Semple P, Stack B, Steward WP. Ifosfamide, carboplatin and etoposide for good prognosis small cell lung
cancer: are four courses inadequate? West of Scotland Lung Cancer Group. Eur J Cancer. 1995 Jun;31A(6):1022-3
98: Goss G, Muldal A, Lohmann R, Taylor M, Lopez P, Armitage G, Steward WP. Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of
the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 1995;13(3):257-60.
99: Steward WP, Dunlop DJ. New drugs in the treatment of non-small cell lung cancer. Ann Oncol. 1995;6 Suppl 1:49-54
100: Steward WP. High dose chemotherapy with haemopoietic support for breast cancer. Eur J Cancer. 1995;31A Suppl 7:S21-4. Review. No abstract available.
101: Vasey PA, Dunlop DJ, Steward WP. Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for metastatic soft tissue sarcoma.
Eur J Cancer. 1995;31A(1):126
102: Dunlop DJ, Fitzsimons EJ, McMurray A, Morrison M, Kyle E, Alcorn MJ, Steward WP. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer. 1994 Nov;70(5):943-5.
103: Ornadel D, Souhami RL, Whelan J, Nooy M, Ruiz de Elvira C, Pringle J, Lewis I, Steward WP, George R, Bridgewater J, et al. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol. 1994 Sep;12(9):1842-8.
104: Steward WP. Efficacy of thymostimulin. Lancet. 1994 Jan 15;343(8890):184.
105: Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. Eur J Cancer. 1994;30A(7):950-5.
106: Holyoake TL, Alcorn MJ, Richmond LJ, Freshney MG, Pearson C, Fitzsimons E, Steward WP, Dunlop DJ, Pragnell IB. Efficient isolation of human CD34 positive hemopoietic progenitor cells by immune panninga. Stem Cells. 1994 Jan;12(1):114-24. Erratum in: Stem Cells (Dayt) 1994 Mar;12(2):233.
107: Holyoake TL, Freshney MG, Sproul AM, Richmond LJ, Alcorn MJ, Steward WP, Fitzsimons E, Dunlop DJ, Franklin IM, Pragnell IB. Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitro. Stem Cells. 1993 Oct;11 Suppl 3:122-8.
108: Steward WP. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet. 1993 Jul 17;342(8864):153-7.
109: McLeay GF, Steward WP. High grade soft tissue sarcoma. Ann Oncol. 1993 Jun;4(6):509-14.
110: Steward WP, Vantongelen K, Verweij J, Thomas D, Van Oosterom AT. Chemotherapy administration and data collection in an EORTC collaborative
group--can we trust the results? Eur J Cancer. 1993;29A(7):943-7.
111: Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, et al. The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 1993;31 Suppl 2:S241-4.
112: Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1993 Jan;11(1):15-21.
113: Blackledge G, Steward WP, Verweij J, Mouridsen H, Bramwell V, Schutte J, van Oosterom A, Dombernowsky P, Buesa J, Van Glabekke M, et al. Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group. Semin Oncol. 1992 Feb;19(1 Suppl 1):14-8.
114: Kerbrat P, Somers R, Verweij J, Crowther D, Tursz T, Santoro A, Steward WP, Lentz MA, van Glabbeke M, Mouridsen HT. Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1992;29A(1):143-4.
115: Steward WP, Dunlop DJ, Cassidy J. Dose intensification of chemotherapy in solid tumours with the use of recombinant human granulocyte-macrophage colony stimulating factor. Behring Inst Mitt. 1991 Dec;(90):44-9.
116: Steward WP, Smith DB, Crowther D. Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma. Ann Oncol. 1991 Sep;2(8):605-6.
117: Dunlop DJ, Steward WP. Recombinant human granulocyte macrophage colony-stimulating factor: current status of clinical trials and potential future applications. Anticancer Drugs. 1991 Aug;2(4):327-37.
118: Steward WP, Verweij J, Somers R, Blackledge G, Clavel M, Van Oosterom AT, Greifenberg B, Soedirman J, Thomas D, Van Glabbeke M, et al. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Oncol. 1991;117 Suppl 4:S193-7.
119: Cassidy J, Poole C, Sharkie E, Steward WP, Kaye SB. The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon. Eur J Cancer. 1991;27(12):1633-4.
120: Steward WP, Christmas SE, Lyon M, Gallagher JT. The synthesis of proteoglycans by human T lymphocytes. Biochim Biophys Acta. 1990 May 22;1052(3):416-25.
121: Steward WP, Scarffe JH, Dirix LY, Chang J, Radford JA, Bonnem E, Crowther D. Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose
melphalan in patients with advanced colon cancer. Br J Cancer. 1990 May;61(5):749-54.
122: Steward WP, Thatcher N, Kaye SB. Clinical applications of myeloid colony stimulating factors. Cancer Treat Rev. 1990 Mar;17(1):77-87. Review. No abstract available.
123: Blackledge G, van Oosterom A, Mouridsen H, Steward WP, Buesa J, Thomas D, Sylvester R, Rouesse J. Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer. 1990 Feb;26(2):139-41.
124: Steward WP, Scarffe JH, Bonnem E, Crowther D. Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor. Int J Cell Cloning. 1990 Jan;8 Suppl 1:335-46.
125: Kamthan AG, Lind MJ, Thatcher N, Steward WP, Bronchud MH, Ranson MR, Stout R. Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with
poor prognosis. Eur J Cancer. 1990;26(6):691-4.
126: Steward WP, Scarffe JH, Dexter TM, Testa NG. Clinical application of hematopoietic growth factors. Immunol Ser. 1990;49:359-78. Review.
127: Crowther D, Scarffe JH, Howell A, Thatcher N, Bronchud M, Steward WP,
Testa N, Dexter M. Growth factor-assisted chemotherapy--the Manchester experience. Ciba Found Symp. 1990;148:201-10; discussion 211-4. Review.
128: Harris M, Blewitt RW, Davies VJ, Steward WP. High-grade non-Hodgkin's lymphoma complicating polypoid nodular lymphoid hyperplasia and multiple lymphomatous polyposis of the intestine. Histopathology. 1989 Oct;15(4):339-50.
129: Steward WP, Mouridsen HT, Kerbrat P, Somers R, Verweij J, Van Oosterom AT, Blackledge G, Havsteen H, Thomas D, Sylvester R. Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1251-3
130: Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, Deakin DP, Crowther D. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989 Feb;59(2):276-82.
131: Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G, Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer. 1989 Jan;59(1):142-5.
132: Steward WP, Scarffe JH. Clinical trials with haemopoietic growth factors. Prog Growth Factor Res. 1989;1(1):1-12
133: Steward WP, Scarffe JH, Austin R, Crowther D. Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor. Behring Inst Mitt. 1988 Aug;(83):324-6.
134: Steward WP, Crowther D, McWilliam LJ, Jones JM, Deakin DP, Todd ID, Blackledge G, Wagstaff J, Scarffe JH, Harris M. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer. 1988 Feb 1;61(3):441-7.
135: Christmas SE, Steward WP, Lyon M, Gallagher JT, Moore M. Chondroitin sulphate proteoglycan production by NK cells and T cells: effects of xylosides on proliferation and cytotoxic function. Immunology. 1988 Feb;63(2):225-31.
136: Smith DB, Fox BW, Thatcher N, Steward WP, Scarffe JH, Wagstaff J, Vezin R, Crowther D. Phase I clinical trial of methylene dimethane sulfonate.Cancer Treat Rep. 1987 Sep;71(9):817-20.
137: Lyon M, Steward WP, Hampson IN, Gallagher JT. Identification of an extended N-acetylated sequence adjacent to the protein-linkage region of fibroblast heparan sulphate. Biochem J. 1987 Mar 1;242(2):493-8.
138: Gallagher JT, Lyon M, Steward WP. Structure and function of heparan sulphate proteoglycans. Biochem J. 1986 Jun 1;236(2):313-25.
139: Smith DB, Thatcher N, Steward WP, Brear G, Carroll KB. A phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol. 1986 Apr;22(4):435-7.
140: Thatcher N, Anderson H, Smith DB, Steward WP, Webb K, Hilton A, Rahman A. Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S30-3.
141: Steward WP, Harris M, Wagstaff J, Scarffe JH, Deakin DP, Todd ID, Crowther D. A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract. Eur J Cancer Clin Oncol. 1985 Oct;21(10):1195-200.
142: Thatcher N, James RD, Steward WP, Barber PV, Feinmann D, Lawson BA, Carroll KB. Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer. 1985 Sep 15;56(6):1332-6.
143: Gasser AB, Steward WP, Wagstaff J, Scarffe JH, Crowther D. Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide. Cancer Treat Rep. 1985 Feb;69(2):225-6. No abstract available.
144: Steward WP, Todd ID, Harris M, Jones JM, Blackledge G, Wagstaff J, Anderson H, Wilkinson PM, Crowther D. A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1984 Jul;20(7):881-9.
145: Anderson H, Deakin DP, Wagstaff J, Jones JM, Todd ID, Wilkinson PM, James RD, Steward WP, Blackledge G, Scarffe JH, et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group. Br J Cancer. 1984 Jun;49(6):695-702.
146: Steward WP, Thatcher N, Edmundson JM, Shiu W, Wilkinson PM. Etoposide infusions for treatment of metastatic lung cancer. Cancer Treat Rep. 1984 Jun;68(6):897-9.
147: Cleland PG, Mosquera I, Steward WP, Foster JB. Prognosis of isolated seizures in adult life. Br Med J (Clin Res Ed). 1981 Nov 21;283(6303):1364.
148: Doucas H, Neal CP, O'reilly K, Dennison AR, Berry DP. Frozen Section Diagnosis of Pancreatic Malignancy: A Sensitive Diagnostic Technique.
Pancreatology. 2006 Mar 9;6(3):210-214
149: Sutton CD, O'Byrne K, Goddard JC, Marshall LJ, Jones L, Garcea G, Dennison AR, Poston G, Lloyd DM, Berry DP. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin Cancer Res. 2005 Sep 15;11(18):6567-73.
150: Court FG, Wemyss-Holden SA, Morrison CP, Teague BD, Dennison AR, Maddern GJ. Postoperative death in sows as a result of gastric mucosal de-gloving at the pars oesophagea. Lab Anim. 2005 Jul;39(3):308-13.
151: Morrison CP, Court FG, Teague BD, Metcalfe MS, Wemyss-Holden SA, Texler M, Dennison AR, Maddern GJ. Endoscopic perductal electrolytic ablation of the pancreas: experimental studies of morbidity and mortality. Dig Dis. 2005;23(1):83-91.
152: Morrison CP, Court FG, Wemyss-Holden SA, Teague BD, Burrell A, Texler M, Metcalfe MS, Dennison AR, Maddern GJ. Perductal electrolytic ablation of the porcine pancreas: a minimally invasive option-studies of morbidity and mortality.
Surg Endosc. 2004 Oct;18(10):1435-41
153: Sutton CD, Garcea G, Pollard C, Berry DP, Dennison AR. The introduction of a nutrition clinical nurse specialist results in a reduction in the rate of catheter sepsis. Clin Nutr. 2005 Apr;24(2):220-3.
154: Lloyd TD, Orr S, Dennison AR. A survey of consumer attitudes to the supply and use of human hepatocytes in the United Kingdom. Altern Lab Anim. 2003 Nov;31(5):483-8.
155: Sutton CD, Garcea G, White SA, O'Leary E, Marshall LJ, Berry DP, Dennison AR. Isolated Roux-loop pancreaticojejunostomy: a series of 61 patients with zero postoperative pancreaticoenteric leaks. J Gastrointest Surg. 2004 Sep-Oct;8(6):701-5.
156: Garcea G, Polemonivi N, O'Leary E, Lloyd TD, Dennison AR, Berry DP.
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases. Eur J Surg Oncol. 2004 Sep;30(7):759-64.
157: Lloyd TD, Orr S, Skett P, Berry DP, Dennison AR. Cryopreservation of hepatocytes: a review of current methods for banking. Cell Tissue Bank. 2003;4(1):3-15.
158: Lloyd TD, Orr S, Patel R, Crees G, Chavda S, Vadyar H, Berry DP, Sherlock D, Dennison AR. Effect of patient, operative and isolation factors on subsequent yield and viability of human hepatocytes for research use. Cell Tissue Bank. 2004;5(2):81-7.
159: Finch JG, Fosh BG, Anthony AA, Texler M, Pearson S, Dennison AR, Maddern GJ. The use of a "liquid" electrode in hepatic electrolysis. J Surg Res. 2004 Aug;120(2):272-7.
160: Lloyd TD, Orr S, Berry DP, Dennison AR. Development of a protocol for cryopreservation of hepatocytes for use in bioartificial liver systems. Ann Clin Lab Sci. 2004 Spring;34(2):165-74.
161: Berry DP, Garcea G, Vanderzon P, Slimani E, Chong C, Dennison AR, Maddern GJ. Augmenting the ablative effect of liver electrolysis: using two electrodes and the pringle maneuver. J Invest Surg. 2004 Mar-Apr;17(2):105-12.
162: Garcea G, Krebs M, Lloyd T, Blanchard K, Dennison AR, Berry D. Haemorrhage from pancreatic pseudocysts presenting as upper gastrointestinal
haemorrhage. Asian J Surg. 2004 Apr;27(2):137-40.
163: Wemyss-Holden SA, Dennison AR, Berry DP, Maddern GJ. Local ablation for unresectable liver tumors: is thermal best? J Hepatobiliary Pancreat Surg. 2004;11(2):97-106.
164: Court FG, Laws PE, Morrison CP, Teague BD, Metcalfe MS, Wemyss-Holden SA, Dennison AR, Maddern GJ. Subtotal hepatectomy: a porcine model for the study of liver regeneration. J Surg Res. 2004 Jan;116(1):181-6.
165: Teague BD, Morrison CP, Court FG, Nguyen T, Wemyss-Holden SA, Dennison AR, Maddern GJ. The lack of a systemic inflammatory response syndrome supports the safety of pancreatic electrolysis: experimental studies. J Surg Res. 2004 Jan;116(1):121-3.
166: Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ. Bioartificial liver support devices: historical perspectives. ANZ J Surg. 2003 Sep;73(9):739-48.
167: Clayton HA, Davies JE, Pollard CA, White SA, Musto PP, Dennison AR. Pancreatectomy with islet autotransplantation for the treatment of severe
chronic pancreatitis: the first 40 patients at the leicester general hospital. Transplantation. 2003 Jul 15;76(1):92-8.
168: Court FG, Wemyss-Holden SA, Morrison CP, Teague BD, Laws PE, Kew J, Dennison AR, Maddern GJ. Segmental nature of the porcine liver and its potential as a model for experimental partial hepatectomy. Br J Surg. 2003 Apr;90(4):440-4.
169: Morrison CP, Teague BD, Court FG, Wemyss-Holden SA, Metcalfe MS, Dennison AR, Maddern GJ. Experimental studies of serum cytokine concentration following pancreatic electrolytic ablation. Med Sci Monit. 2003 Jan;9(1):BR43-6.
170: Sutton CD, Marshall LJ, White SA, Berry DP, Dennison AR. Kehr's sign - a rare cause: spontaneous phrenic artery rupture. ANZ J Surg. 2002 Dec;72(12):913-4. No abstract available.
171: Morrison CP, Wemyss-Holden SA, Court FG, Teague BD, Dennison AR, Maddern GJ. In vivo pancreatic-specific hypothermia: retrograde ductal perfusion
experimental studies. Transplant Proc. 2002 Dec;34(8):3351-3. No abstract available.
172: Sutton CD, White SA, Marshall LJ, Dennison AR, Thomas WM. Idiopathic chronic ulcerative enteritis--the role of radical surgical resection. Dig Surg. 2002;19(5):406-8.
173: Wemyss-Holden SA, Court FG, Morrison CP, Teague BD, Burrell A, Morales DR, Rodgers N, Anthony AA, Metcalfe MS, Dennison AR, Maddern GJ. Palliation of pancreatic cancer using electrolytic ablation. Surg Endosc. 2003 Feb;17(2):207-11.
174: Wemyss-Holden SA, Berry DP, Robertson GS, Dennison AR, De La M Hall P,
Maddern GJ. Electrolytic ablation as an adjunct to liver resection: Safety and efficacy in patients. ANZ J Surg. 2002 Aug;72(8):589-93.
175: Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ. The mystery of liver regeneration. Br J Surg. 2002 Sep;89(9):1089-95
176: Teague BD, Wemyss-Holden SA, Fosh BG, Dennison AR, Maddern GJ. Electrolysis and other local ablative treatments for non-resectable colorectal
liver metastases. ANZ J Surg. 2002 Feb;72(2):137-41
177: Marshall LJ, Sutton CD, White SA, Mackay H, Dennison AR. Syndrome X induced by carcinoid syndrome secondary to a cervical neuroendocrine primary tumour.ANZ J Surg. 2002 May;72(5):372-4.
178: Wemyss-Holden SA, Dennison AR, Finch GJ, Hall Pd Pde L, Maddern GJ. Electrolytic ablation as an adjunct to liver resection: experimental studies of
predictability and safety. Br J Surg. 2002 May;89(5):579-85.
179: Finch JG, Fosh B, Anthony A, Slimani E, Texler M, Berry DP, Dennison AR, Maddern GJ. Liver electrolysis: pH can reliably monitor the extent of hepatic ablation in pigs. Clin Sci (Lond). 2002 Apr;102(4):389-95.
180: Morrison CP, Wemyss-Holden SA, Dennison AR, Maddern GJ. Islet yield remains a problem in islet autotransplantation. Arch Surg. 2002 Jan;137(1):80-3.
181: Clayton HA, Davies JE, Sutton CD, Bell PR, Dennison AR. A coculture model of intrahepatic islet transplantation: activation of Kupffer cells by islets and acinar tissue. Cell Transplant. 2001 Jan-Feb;10(1):101-8.
182: White SA, Pollard C, Davies JE, Sutton CD, Hales CN, Dennison AR. Temporal relationship of insulin, intact proinsulin and split proinsulin after
islet autotransplantation. Transplant Proc. 2001 Feb-Mar;33(1-2):680.
183: White SA, Davies JE, Pollard C, Swift SM, Clayton HA, Sutton CD,
Weymss-Holden S, Musto PP, Berry DP, Dennison AR. Pancreas resection and islet autotransplantation for end-stage chronic pancreatitis. Ann Surg. 2001 Mar;233(3):423-31.
184: Berry DP, Dennison AR, Ward R, Maddern GJ. Electrolytic ablation of colorectal liver metastases: 1-year histological patient follow-up.
Dig Surg. 2000;17(5):518-9.
185: White SA, Robertson GS, London NJ, Dennison AR. Human islet autotransplantation to prevent diabetes after pancreas resection. Dig Surg. 2000;17(5):439-50
186: Wemyss-Holden SA, Robertson GS, Hall PD, Dennison AR, Maddern GJ. Electrolytic treatment of colorectal liver tumour deposits in a rat model: a
technique with potential for patients with unresectable liver tumours. Dig Dis. 2000;18(2):50-7.
187: White SA, Sutton CD, Robertson GS, Furness PN, Dennison AR. Incidental adult nesidioblastosis after distal pancreatectomy for endocrine
microadenoma. Eur J Gastroenterol Hepatol. 2000 Oct;12(10):1147-9.
188: Wemyss-Holden SA, Robertson GS, Dennison AR, de la M Hall P, Fothergill JC, Jones B, Maddern GJ. Electrochemical lesions in the rat liver support its potential for treatment of liver tumors. J Surg Res. 2000 Sep;93(1):55-62.
189: Wemyss-Holden SA, de la M Hall P, Robertson GS, Dennison AR, Vanderzon PS, Maddern GJ. The safety of electrolytically induced hepatic necrosis in a pig model. Aust N Z J Surg. 2000 Aug;70(8):607-12.
190: White SA, Sutton CD, Weymss-Holden S, Berry DP, Pollard C, Rees Y, Dennison AR. The feasibility of spleen-preserving pancreatectomy for end-stage chronic pancreatitis. Am J Surg. 2000 Apr;179(4):294-7.
191: Sutton CD, White SA, Berry DP, Dennison AR. Intrahepatic biliary cystadenoma causing luminal common bile duct obstruction.Dig Surg. 2000;17(3):297-9.
192: White SA, London NJ, Johnson PR, Davies JE, Pollard C, Contractor HH, Hughes DP, Robertson GS, Musto PP, Dennison AR. The risks of total pancreatectomy and splenic islet autotransplantation. Cell Transplant. 2000 Jan-Feb;9(1):19-24.
193: Wemyss-Holden SA, Robertson GS, Dennison AR, Vanderzon PS, Hall PM, Maddern GJ. A new treatment for unresectable liver tumours: long-term studies of
electrolytic lesions in the pig liver. Clin Sci (Lond). 2000 May;98(5):561-7.
194: White SA, Sutton CD, Berry DP, Chillistone D, Rees Y, Dennison AR. Experience of combined endoscopic percutaneous stenting with ultrasound
guidance for drainage of pancreatic pseudocycts. Ann R Coll Surg Engl. 2000 Jan;82(1):11-5.
195: White SA, Sutton CD, Berry DP, Dennison AR. Value of splenic preservation during distal pancreatectomy for chronic pancreatitis. Br J Surg. 2000 Jan;87(1):124.
196: Sutton CD, White SA, Robertson GS, Dennison AR. Chronic unilateral lymphoedema caused by a pancreatic pseudocyst. Int J Pancreatol. 1999 Apr;25(2):143-5.
197: White SA, Robertson GS, Davies JE, Rees Y, London NJ, Dennison AR. Splenic infarction after total pancreatectomy and autologous islet
transplantation into the spleen. Pancreas. 1999 May;18(4):419-21. No abstract available.
198: Johnson PR, White SA, Robertson GS, Koppiker N, Burden AC, Dennison AR, London NJ. Pancreatic islet autotransplantation combined with total pancreatectomy for the treatment of chronic pancreatitis--the Leicester experience. J Mol Med. 1999 Jan;77(1):130-2.
199: Robertson GS, Wemyss-Holden SA, Dennison AR, Hall PM, Baxter P, Maddern GJ. Experimental study of electrolysis-induced hepatic necrosis.
Br J Surg. 1998 Sep;85(9):1212-6.
200: Baxter PS, Wemyss-Holden SA, Dennison AR, Maddern GJ. Electrochemically induced hepatic necrosis: the next step forward in patients with unresectable liver tumours? Aust N Z J Surg. 1998 Sep;68(9):637-40.
201: White SA, Koppiker NP, Burden AC, Davies MJ, Davies JE, Clayton HA, Swift SM, Hales CN, Dennison AR, London NJ. Insulin deficiency and increased intact and 32/33 split proinsulin secretion following human islet autotransplantation. Transplant Proc. 1998 Mar;30(2):627-8. No abstract available.
202: Swift SM, White SA, Clayton HA, Kimber D, London NJ, Dennison AR. Intraportal human islet autotransplantation: an immunohistochemical study of
islets in situ. Transplant Proc. 1998 Mar;30(2):417
203: White SA, Birch JF, Forshaw MJ, Power DM, Dennison AR. Splenic human islet autotransplantation: anatomical variations of splenic venous drainage.
Transplant Proc. 1998 Mar;30(2):314
204: White SA, Dennison AR, Swift SM, Davies JE, Clayton HA, Burden AC, Musto PP, Johnson PR, Wicks A, London NJ. Intraportal and splenic human islet autotransplantation combined with total pancreatectomy. Transplant Proc. 1998 Mar;30(2):312-3.
205: Davies JE, White SA, Clayton HA, Swift SM, Dennison AR. Inflammatory response after total pancreatectomy and islet autotransplantation. Transplant Proc. 1998 Mar;30(2):307.
206: Robertson GS, Dennison AR, Johnson PR, London NJ. A review of pancreatic islet autotransplantation. Hepatogastroenterology. 1998 Jan-Feb;45(19):226-35.
207: Robertson GS, Thomas M, Jamieson J, Veitch PS, Dennison AR. Palliation of oesophageal carcinoma using the argon beam coagulator. Br J Surg. 1996 Dec;83(12):1769-71.
208: Dennison AR, Kerrigan DD, Oakley N, Paraskevopoulos JA, Peck R, Collins MC, Johnson AG. The role of the radiologist in surgical management: an audit of clinico-radiological conferences. Postgrad Med J. 1996 Aug;72(850):481-3.
209: Cassell OC, Oakley N, Forrest AR, Thomas WE, Dennison AR. Randomized comparison of oral and intravenous fluid regimens after gallbladder surgery. J R Soc Med. 1996 May;89(5):249-52.
210: Dennison AR, Paraskevopoulos JA, Kerrigan DD, Shorthouse AJ. New thoughts on the aetiology of haemorrhoids and the development of non-operative methods for their management. Minerva Chir. 1996 Apr;51(4):209-16.
211: Oakley N, Dennison AR, Shorthouse AJ. A prospective audit of simple mastectomy under local anaesthesia. Eur J Surg Oncol. 1996 Apr;22(2):134-6. Erratum in: Eur J Surg Oncol 1996Oct;22(5):560.
212: Coakley FV, Owen RJ, Rees Y, Dennison AR. Case report: bladder opacification following enteral iopamidol as a sign of occult intestinal infarction.
Br J Radiol. 1996 Jan;69(817):76-7.
213: Dennison AR, Azoulay D, Oakley N, Baer H, Paraskevopoulos JA, Maddern GJ. What should I do about my patient's gall stones? Postgrad Med J. 1995 Dec;71(842):725-9.
214: Baer HU, Rhyner M, Stain SC, Glauser PW, Dennison AR, Maddern GJ, Blumgart LH. The effect of communication between the right and left liver on the outcome of surgical drainage for jaundice due to malignant obstruction at the hilus of the liver. HPB Surg. 1994;8(1):27-31.
215: Mason PF, Rooney SR, Laing RW, Dennison AR. Trivial chest injury: a case for vigilance. Injury. 1993 Dec;24(10):688-90
216: Dennison AR, Azoulay D, Maddern GJ. Living related hepatic donation: Prometheus or Pandora's box? Aust N Z J Surg. 1993 Nov;63(11):835-9. No abstract available.
217: Blumgart LH, Baer HU, Czerniak A, Zimmermann A, Dennison AR. Extended left hepatectomy: technical aspects of an evolving procedure. Br J Surg. 1993 Jul;80(7):903-6.
218: Kerrigan DD, Thevasagayam RS, Woods TO, Mc Welch I, Thomas WE, Shorthouse AJ, Dennison AR. Who's afraid of informed consent? BMJ. 1993 Jan 30;306(6873):298-300.
219: Bismuth H, Dennison AR. Segmental liver resection. Adv Surg. 1993;26:189-208. Review.
220: Baer HU, Stain SC, Dennison AR, Eggers B, Blumgart LH. Improvements in survival by aggressive resections of hilar cholangiocarcinoma. Ann Surg. 1993 Jan;217(1):20-7.
221: Baer HU, Dennison AR, Mouton W, Stain SC, Zimmermann A, Blumgart LH. Enucleation of giant hemangiomas of the liver. Technical and pathologic aspects
of a neglected procedure. Ann Surg. 1992 Dec;216(6):673-6.
222: Stain SC, Baer HU, Dennison AR, Blumgart LH. Current management of hilar cholangiocarcinoma. Surg Gynecol Obstet. 1992 Dec;175(6):579-88.
223: Paraskevopoulos JA, Dennison AR, Ross B, Johnson AG. Primary carcinoma of the gallbladder: a 10-year experience. Ann R Coll Surg Engl. 1992 May;74(3):222-4.
224: Maddern GJ, Dennison AR. Central European surgical training. Aust N Z J Surg. 1992 May;62(5):397-9.
225: Maddern GJ, Dennison AR, Blumgart LH. Fatal ascaris pancreatitis: an uncommon problem in the west. Gut. 1992 Mar;33(3):402-3.
226: Dennison AR, Maddern GJ. A temporary chef de clinique. Lancet. 1991 Nov 16;338(8777):1255-6.
227: Baer HU, Dennison AR, Maddern GJ, Blumgart LH. Subtotal hepatectomy: a new procedure based on the inferior right hepatic vein. Br J Surg. 1991 Oct;78(10):1221-2.
228: Paraskevopoulos JA, Gunning AJ, Dennison AR. The changing pattern of thoracic surgery in the United Kingdom 1963-1982. J R Soc Med. 1991 Aug;84(8):484-7.
229: Paraskevopoulos JA, Stephenson TJ, Dennison AR. Primary leiomyosarcoma of the liver. HPB Surg. 1991 Jun;4(2):157-62; discussion 162-3.
230: Charnley RM, Morris DL, Dennison AR, Amar SS, Hardcastle JD. Detection of colorectal liver metastases using intraoperative ultrasonography.
Br J Surg. 1991 Jan;78(1):45-8.
231: Paraskevopoulos JA, Dennison AR, Johnson AG. Primary carcinoma of the gallbladder. HPB Surg. 1991;4(4):277-89
232: Hands LJ, Papavramidis S, Bishop H, Dennison AR, McIntyre RL, Kettlewell MG. The natural history of peptic oesophageal strictures treated by dilatation and antireflux therapy alone. Ann R Coll Surg Engl. 1989 Sep;71(5):306-9; discussion 9-10.
233: Dennison AR, Whiston RJ, Rooney S, Morris DL. The management of hemorrhoids. Am J Gastroenterol. 1989 May;84(5):475-81.
234: Dennis MJ, Dennison AR, Morris DL. Parasitic causes of obstructive jaundice. Ann Trop Med Parasitol. 1989 Apr;83(2):159-61.
235: Dennison AR, Wherry DC, Morris DL. Hemorrhoids. Nonoperative management. Surg Clin North Am. 1988 Dec;68(6):1401-9. Review.
236: Clarke PJ, Dennison AR, Ball MJ, Hands LJ, Kettlewell MG. Experiences with an MCT-containing parenteral nutrition regimen in patients
receiving routine TPN. Beitr Infusionther Klin Ernahr. 1988;20:119-25.
237: Dennison AR, Ball M, Hands LJ, Crowe PJ, Watkins RM, Kettlewell M. Total parental nutrition using conventional and medium chain triglycerides:
effect on liver function tests, complement, and nitrogen balance. JPEN J Parenter Enteral Nutr. 1988 Jan-Feb;12(1):15-9.
238: Collin J, Dennison AR, Watkins RM, Millard PR, Morris PJ. Segmental small intestinal allografts. II. Inadequate function with cyclosporine immunosuppression: evidence of a protein-losing enteropathy.Transplantation. 1987 Oct;44(4):479-83.
239: Dennison AR, Collin J, Watkins RM, Millard PR, Morris PJ. Segmental small intestinal allografts in the dog. I. Morphological and functional indices of rejection. Transplantation. 1987 Oct;44(4):474-8.
240: Clarke PJ, Ball MJ, Hands LJ, Dennison AR, Tunbridge A, White K, Kettlewell MG. Use of a lipid containing medium chain triglycerides in patients receiving TPN: a randomized prospective trial.Br J Surg. 1987 Aug;74(8):701-4.
241: Dennison AR, Collin J, Watkins RM, Millard PR, Morris PJ. Absorptive and motor function of orthotopically vascularized segmental ileal
autografts. Br J Surg. 1987 Mar;74(3):187-91.
242: Dennison AR, Watkins RM, Sarr MJ, Lee EC. Adenocarcinoma complicating a duodenal diverticulum. J R Coll Surg Edinb. 1987 Feb;32(1):44-6. No abstract available.
243: Dennison AR, Tibbs DJ. Varicocele and varicose veins compared. A basis for logical surgery. Urology. 1986 Sep;28(3):211-7.
244: Dennison AR, Ball M, Crowe PJ, White K, Hands L, Watkins RM, Kettlewell M. The metabolic consequences of infusing emulsions containing medium chain
triglycerides for parenteral nutrition: a comparative study with conventional lipid. Ann R Coll Surg Engl. 1986 May;68(3):119-21.
245: Dawes RF, Royle GT, Dennison AR, Crowe PJ, Ball M. Metabolic studies of a lipid emulsion containing medium-chain triglyceride in perioperative and total parenteral nutrition infusions. World J Surg. 1986 Feb;10(1):38-46. No abstract available.
246: Crowe PJ, Dennison AR, Royle GT. A new intravenous emulsion containing medium-chain triglyceride: studies of its metabolic effects in the perioperative period compared with a conventional long-chain triglyceride emulsion. JPEN J Parenter Enteral Nutr. 1985 Nov-Dec;9(6):720-4.
247: Watkins RM, Dennison AR, Collin J. Drug therapy and perforated peptic ulcer. Gut. 1985 Sep;26(9):981-2
248: Dennison AR, Alcock CJ, Mason CH, Britton BJ, Paine CH. Non-chromaffin paraganglioma presenting as a pelvic metastasis. J R Soc Med. 1985 Sep;78(9):763-5.
249: Dennison AR, Watkins RM, Ward ME, Lee EC. Simple mastectomy under local anaesthesia. Ann R Coll Surg Engl. 1985 Jul;67(4):243-4.
250: Dennison AR, Watkins RM, Gunning AJ. Simultaneous aortic and pulmonary artery aneurysms due to giant cell arteritis. Thorax. 1985 Feb;40(2):156-7.
251: Watkins RM, Dennison AR, Collin J. What has happened to perforated peptic ulcer? Br J Surg. 1984 Oct;71(10):774-6.
252: Dennison AR, Britton BJ. Penetrating anorectal injury. An unrecognized hazard for surgeons. Dis Colon Rectum. 1984 Sep;27(9):624-5.
253: Dennison AR, Royle GT. Acute pancreatitis--presentation as a discoloured lump in the groin. Postgrad Med J. 1984 May;60(703):374-5. No abstract available.
254: Northeast AD, Dennison AR, Lee EG. Sigmoid volvulus: new thoughts on the epidemiology. Dis Colon Rectum. 1984 Apr;27(4):260-1.
255: Lloyd TD, Malin G, Pugsley H, Garcea A, Garcea G, Dennison A, Berry DP, Kelly MJ. Women presenting with lower abdominal pain: a missed opportunity for Chlamydia screening? Surgeon. 2006 Feb;4(1):15-9.
256: Norwood MG, Lykostratis H, Garcea G, Berry DP. Acute colonic pseudo-obstruction following major orthopaedic surgery. Colorectal Dis. 2005 Sep;7(5):496-9.
257: Garcea G, Thomasset S, Berry DP, Tordoff S. Percutaneous splanchnic nerve radiofrequency ablation for chronic abdominal pain. ANZ J Surg. 2005 Aug;75(8):640-4.
259: Doucas H, Garcea G, Neal CP, Manson MM, Berry DP. Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer. 2005 Feb;41(3):365-79
260: Thomasset SC, Berry DP. Spontaneous intramural esophageal hematoma.
J Gastrointest Surg. 2005 Jan;9(1):155-6.
261: Garcea G, Malin G, Lloyd T, Brundle S, Kelly M, Berry D. Patient information following emergency laparoscopy for right iliac fossa pain.Surg Laparosc Endosc Percutan Tech. 2004 Jun;14(3):136-40. Erratum in: Surg Laparosc Endosc Percutan Tech. 2004 Dec;14(6):357.
262: Norwood MG, Bown MJ, Furness PN, Berry DP. Actinomycosis of the sigmoid colon: an unusual cause of large bowel perforation. ANZ J Surg. 2004 Sep;74(9):816-8.
263: Garcea G, Thomasset S, McClelland L, Leslie A, Berry DP. Impact of a critical care outreach team on critical care readmissions and mortality. Acta Anaesthesiol Scand. 2004 Oct;48(9):1096-100.
264: Garcea G, Polimenovi N, Mulcahy K, Lloyd T, Rees Y, Berry DP. Diagnostic value of MRCP in the management of hilar strictures after extended
liver resection. Clin Radiol. 2004 Sep;59(9):846-8. No abstract available.
265: Sutton CD, Marshall LJ, Williams N, Berry DP, Thomas WM, Kelly MJ. Colo-rectal anastomotic leakage often masquerades as a cardiac complication. Colorectal Dis. 2004 Jan;6(1):21-2.
267: Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer. 2003 Oct;39(15):2150-64.
270: Sutton CD, Marshall LJ, White SA, Flint N, Berry DP, Kelly MJ. Ten-year experience of endoscopic transanal resection. Ann Surg. 2002 Mar;235(3):355-62.
271: Sutton CD, White SA, Marshall LJ, Berry DP, Veitch PS. Endoscopic-assisted intrathoracic oesophagogastrostomy without thoracotomy for tumours of the lower oesophagus and cardia.Eur J Surg Oncol. 2002 Feb;28(1):46-8.
272: Goddard JC, Sutton CD, Berry DP, O'Byrne KJ, Kockelbergh RC. The use of microvessel density in assessing human urological tumours. BJU Int. 2001 Jun;87(9):866-75.
273: Sutton CD, Gilmour JP, Berry DP, Lewis MH. The evolution of a vascular surgeon at a district general hospital: is sub-specialisation inevitable? Ann R Coll Surg Engl. 2000 Jul;82(4):272-4.
274: Tranter SE, Maddern GJ, Berry DP. Metastatic malignant fibrous histiocytoma: a rare cause of small bowel intussusception. Aust N Z J Surg. 2000 Apr;70(4):317-8.
275: Nguyen NQ, Maddern GJ, Berry DP. Endoscopic retrograde cholangiopancreatography-induced haemolytic uraemic syndrome. Aust N Z J Surg. 2000 Mar;70(3):235-6. Review. No abstract available.
276: Tranter SE, Maddern GJ, Berry DP. Inflammatory conditions of the common bile duct.Aust N Z J Surg. 2000 Feb;70(2):95-7.
277: Birch JF, White SA, Berry DP, Veitch PS. A cost-benefit comparison of self-expanding metal stents and Atkinson tubes for the palliation of obstructing esophageal tumors. Dis Esophagus. 1998 Jul;11(3):172-6.
278: Berry DP, Harding KG, Stanton MR, Jasani B, Ehrlich HP. Human wound contraction: collagen organization, fibroblasts, and myofibroblasts. Plast Reconstr Surg. 1998 Jul;102(1):124-31; discussion 132-4.
279: Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg. 1997 Sep;84(9):1274-6.
280: Berry DP, Scholefield JH. Closure of loop ileostomy. Br J Surg. 1997 Apr;84(4):524
281: Scholefield JH, Berry DP, Armitage NC, Wastie ML. Magnetic resonance imaging in the management of fistula in ano. Int J Colorectal Dis. 1997;12(5):276-9.
282: Berry DP, Bale S, Harding KG. Dressings for treating cavity wounds.
J Wound Care. 1996 Jan;5(1):10-7.
283: Berry DP, Harding KG. Potential pitfalls of minor surgery in general practice.
Br J Gen Pract. 1993 Sep;43(374):358-9
284: Robinson MH, Berry DP, Vellacott KD, Moshakis V, Hardcastle JD. Screening for colorectal cancer. Lancet. 1993 Jul 24;342(8865):241.
285: Berry DP, Vellacott KD. High jejunal obstruction: a complication of percutaneous endoscopic gastrostomy. Br J Surg. 1992 Nov;79(11):1171.
286: Berry DP, Harding KG. Treatment of natal cleft sinus. BMJ. 1992 Aug 1;305(6848)
287: Farmilo RW, Johnston DH, Berry DP, Semeraro D. Primary adenocarcinoma of the jejunum and ileum. J R Coll Surg Edinb. 1988 Jun;33(3):124-6.
292: Bagul A, Taha R, Metcalfe MS, Brook NR, Nicholson ML. Pre-incision infiltration of local anesthetic reduces postoperative pain withno effects on bruising and wound cosmesis after thyroid surgery. Thyroid. 2005 Nov;15(11):1245-8.
293: Mullin EJ, Metcalfe MS, Maddern GJ. How much liver resection is too much?
Am J Surg. 2005 Jul;190(1):87-97
294: Metcalfe MS, Norwood MG, Miller AS, Hemingway D. Unreasonable expectations in emergency colorectal cancer surgery. Colorectal Dis. 2005 May;7(3):275-8.
295: Saunders RN, Karoo R, Metcalfe MS, Nicholson ML. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure. Postgrad Med J. 2005 Apr;81(954):255-8.
296: Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg. 2004 Nov;139(11):1168-72.
297: Nicholson ML, Hosgood SA, Metcalfe MS, Waller JR, Brook NR. A comparison of renal preservation by cold storage and machine perfusion using
a porcine autotransplant model. Transplantation. 2004 Aug 15;78(3):333-7.
298: Metcalfe MS, Mullin EJ, Maddern GJ. Choice of surveillance after hepatectomy for colorectal metastases. Arch Surg. 2004 Jul;139(7):749-54.
299: Mullin EJ, Metcalfe MS, Maddern GJ. Artificial liver support: potential to retard regeneration? Arch Surg. 2004 Jun;139(6):670-7. Review.
300: Metcalfe MS, Ong T, Bruening MH, Iswariah H, Wemyss-Holden SA, Maddern GJ. Is laparoscopic intraoperative cholangiogram a matter of routine? Am J Surg. 2004 Apr;187(4):475-81. Review.
301: Martin CR, Tweed AE, Metcalfe MS. A psychometric evaluation of the Hospital Anxiety and Depression Scale in patients diagnosed with end-stage renal disease. Br J Clin Psychol. 2004 Mar;43(Pt 1):51-64.
302: Metcalfe MS, Bridgewater FH, Mullin EJ, Maddern GJ. Useless and dangerous--fine needle aspiration of hepatic colorectal metastases.
BMJ. 2004 Feb 28;328(7438):507-8.
303: Leopardi LN, Metcalfe MS, Forde A, Maddern GJ. Ite Boerema--surgeon and engineer with a double-Dutch legacy to medical
technology. Surgery. 2004 Jan;135(1):99-103.
304: Metcalfe MS, Maddern GJ. Laparoscopic staging of upper gastrointestinal malignancy.ANZ J Surg. 2003 Oct;73(10):782-3.
305: Metcalfe MS, Close JS, Iswariah H, Morrison C, Wemyss-Holden SA, Maddern GJ. The value of laparoscopic staging for patients with colorectal metastases. Arch Surg. 2003 Jul;138(7):770-2.
306: Metcalfe MS, Wemyss-Holden SA, Maddern GJ. Management dilemmas with choledochal cysts. Arch Surg. 2003 Mar;138(3):333-9. Review.
307: Metcalfe MS, Jain S, Waller JR, Saunders RN, Bicknell GR, Nicholson ML. A randomized trial of mycophenolate mofetil versus azathioprine as calcineurin
inhibitor sparing agents in the treatment of chronic allograft nephropathy. Transplant Proc. 2002 Aug;34(5):1812-4. No abstract available.
308: Waller JR, Murphy GJ, Metcalfe MS, Sandford RM, Pattenden CJ, Nicholson ML. Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy.Transplant Proc. 2002 Aug;34(5):1587-8.
309: Waller JR, Toomey D, Metcalfe MS, Margolin SB, Nicholson ML. Pirfenidone inhibits early neointimal proliferation following arterial injury.
Transplant Proc. 2002 Aug;34(5):1486-8.
310: Waller JR, Metcalfe MS, Nicholson ML. Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury. Transplant Proc. 2002 Aug;34(5):1481-3
311: Metcalfe MS, Waller JR, Hosgood SA, Shaw M, Hassanein W, Nicholson ML. A paired study comparing the efficacy of renal preservation by normothermic
autologous blood perfusion and hypothermic pulsatile perfusion. Transplant Proc. 2002 Aug;34(5):1473-4.
312: Waller JR, Murphy GJ, Metcalfe MS, Bicknell GR, Saunders RN, Margolin SB, Nicholson ML. Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury.Transplant Proc. 2001 Nov-Dec;33(7-8):3816-8.
313: Metcalfe MS, Waller JR, Saunders RN, Veitch PS, Nicholson ML. Measuring intrarenal vascular resistance during machine perfusion preservation
does not improve the assessment of renal viability made on clinical grounds. Transplant Proc. 2001 Nov-Dec;33(7-8):3745-6.
314: Metcalfe MS, Mann CD, Waller JR, Saunders RN, Roehlke W, Nicholson ML. Normothermic perfusion of ischaemically damaged porcine kidneys: an evaluation
of ex vivo function. Transplant Proc. 2001 Nov-Dec;33(7-8):3743-4. No abstract available.
315: Metcalfe MS, Tweed A, White SA, Taylor R, Mullin E, Saunders RN, Waller JR, Wrigglesworth R, Nicholson ML. Quality of life for renal transplant recipients of organs from non-heart-beating donors, heart-beating cadaveric donors, and living-related donors. Transplant Proc. 2001 Nov-Dec;33(7-8):3403-4.
316: Kimber RM, Metcalfe MS, White SA, Nicholson ML. Use of non-heart-beating donors in renal transplantation. Postgrad Med J. 2001 Nov;77(913):681-5.
317: Metcalfe MS, Butterworth PC, White SA, Saunders RN, Murphy GJ, Taub N, Veitch PS, Nicholson ML. A case-control comparison of the results of renal transplantation from heart-beating and non-heart-beating donors. Transplantation. 2001 Jun 15;71(11):1556-9.
318: Metcalfe MS, White SA, Saunders RN, Murphy GJ, Horsburgh T, Knight AJ, Nicholson ML. Long-term results of renal transplantation using organs from non-heart-beating donors. Transplant Proc. 2001 Feb-Mar;33(1-2):826. No abstract available.
319: Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001 Jan;59(1):3-16. Review.
320: Metcalfe MS, Nicholson ML. Non-heart-beating donors for renal transplantation. Lancet. 2000 Nov 25;356(9244):1853; author reply 1854. No abstract available.
321: Nicholson ML, Metcalfe MS, White SA, Waller JR, Doughman TM, Horsburgh T, Feehally J, Carr SJ, Veitch PS. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. Kidney Int. 2000 Dec;58(6):2585-91. Erratum in: Kidney Int 2001 Feb;59(2):821.
322: Metcalfe MS, Hemingway D. Testing for anastomotic integrity after reversal of loop ileostomy. Ann R Coll Surg Engl. 2000 Sep;82(5):344-5.
323: Metcalfe MS, Rees Y, Morgan P, O'Reilly K, Sandhu DP. Sarcoidosis presenting as a testicular mass. Br J Urol. 1998 Nov;82(5):769-70. No abstract available.
327: Metcalfe M, Mann C, Mullin E, Maddern G. Detecting curable disease following hepatectomy for colorectal metastases.ANZ J Surg. 2005 Jul;75(7):524-7.
328: Iswariah H, Metcalfe M, Morrison CP, Maddern GJ. Facilitation of open spigelian hernia repair by laparoscopic location of the hernial defect. Surg Endosc. 2003 May;17(5):832.
329: Iswariah H, Metcalfe M, Lituri D, Maddern GJ. Mucinous cystadenoma of the appendix. ANZ J Surg. 2004 Oct;74(10):918-9.
330: Ruso L, Taruselli R, Metcalfe M, Maddern G. Resection of the angle of Treitz and distal diverticulization of the duodenum in penetrating abdominal injuries. Dig Surg. 2004;21(3):177-80; discussion 781.
331: Murphy GJ, Saunders R, Metcalfe M, Nicholson ML. Elbow fistulas using autogeneous vein: patency rates and results of revision. Postgrad Med J. 2002 Aug;78(922):483-6.
332: Jain S, Metcalfe M, White SA, Furness PN, Nicholson ML. Chronic allograft nephropathy: a prospective randomised trial of cyclosporine reduction with or without mycophenolate mofetil. Transplant Proc. 2001 May;33(3):2165-6. No abstract available.
